In addition, the Company is using its proprietary nucleic acid drug discovery platform to refocus research and developments efforts on expanding its clinical pipeline with the addition of two orphan disease programs.
"The last two years have been very challenging for the company, but as a result of recent progress, I believe we are solidly on a turnaround path and well on our way to building significant shareholder value," stated
Nucleic acids are extremely promising for the treatment of complex and orphan diseases, yet efficient and cell-specific delivery of oligonucleotide therapeutics remains a barrier to clinical progress. Furthermore, as many illnesses are multi-system diseases (i.e., they affect more than one organ or physiological process), treatment will likely not be successful using a singular therapeutic or delivery regimen. Successful treatment may require a customizable approach over the course of care that employs multiple therapeutics, each with a unique biological target, dose, and delivery mechanism. The ability to develop both single- and double-stranded oligonucleotide constructs and combine them with a breadth of delivery technologies will likely provide the greatest chance for clinical success.
Most Popular Stories
- PBS Series Examines America's Demographic Shift
- Americans Bet Big on Gambling Industry
- Petri Likely Broke House Ethics Rules
- California's Ban on Plastic Bags: What Now?
- Texas Sees Gains in Hispanic College Enrollment
- Exxon Gives Nod to Fracking Risks
- Morgan: 'Can't Believe' Wal-Mart Blaming Him
- Can You Be Fired for Using Medical Marijuana?
- Wealth Gap Widens as Rich Spend More on Kids' Education
- Lack of Sea Ice Brings 35,000 Walruses Ashore